Can a diabetes drug protect blood vessels in type 1 diabetes?

NCT ID NCT05478707

Recruiting now Disease control Sponsor: AdventHealth Translational Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether dulaglutide, a drug used for type 2 diabetes, can improve small blood vessel function in adults with type 1 diabetes. The study involves 47 participants aged 18-40 with long-standing type 1 diabetes. Researchers measure blood flow and insulin sensitivity to see if the drug reduces oxidative stress and improves endothelial health. The trial is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dulaglutide (a GLP-1 receptor agonist drug, similar to medications used for type 2 diabetes)
What this could lead to: If successful, this could point toward a new way to protect small blood vessels in people with type 1 diabetes, potentially reducing complications like kidney or eye disease.
What could go wrong: This is a small, early-phase trial that is currently suspended. It tests a drug not yet approved for type 1 diabetes, and results may not lead to a new treatment. Risks include side effects from dulaglutide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1 ENDOTHELIAL DYSFUNCTION

Contacts and locations

Locations

AdventHealth Translational Research Institute
RECRUITING

Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.